pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Ophthalmology · news · pharmadog
← back to Ophthalmology
News · Ophthalmology
169
stories
Jun 11, 26
Opinion: How long Covid’s scientific stalemate made it politically erasable
stat
Jun 10, 26
Ethyreal starts up with $101M and takes aim at a pair of immune diseases
biopharma dive
Jun 10, 26
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
biopharma dive
Jun 10, 26
Ethyreal lands $101M to treat both Graves' and thyroid eye disease
endpoints
Jun 9, 26
Post-Hoc Live: How much is everyone in biopharma getting paid?
endpoints
Jun 8, 26
City banks nearly $100M for next-gen RNAi drugs
biopharma dive
Jun 8, 26
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
biopharma dive
Jun 8, 26
Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs
endpoints
Jun 3, 26
Lilly, Ascidian link up in RNA exon editing pact
biopharma dive
Jun 1, 26
Oculis’ eye drops for diabetic macular edema flunk Phase 3 test
endpoints
May 18, 26
Regeneron immunotherapy combo comes up short in melanoma trial
biopharma dive
May 15, 26
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
biopharma dive
May 13, 26
Opinion: The hantavirus is a wake-up call. Will the Trump administration answer it?
stat
May 13, 26
STAT+: What the Trump administration wants in its next FDA leader
stat
May 13, 26
Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3
endpoints
May 12, 26
A year after Vertex’s big launch, pain drug research faces a pivotal moment
biopharma dive
May 11, 26
Institutional Perspectives on Treatment Thresholds in PLGG
onclive
May 9, 26
Opinion: Dr. Glaucomflecken wants the corporatization of medicine to be national news
stat
May 7, 26
Astellas touts data from early test of stem cell-derived eye therapy
endpoints
May 7, 26
Opinion: Eugene Braunwald, ‘father of modern cardiology,’ told me he had two dreams. One came true
stat
May 6, 26
Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
biopharma dive
May 6, 26
STAT+: When the path to good AI is littered with bad data
stat
May 6, 26
STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
stat
May 6, 26
HHS tackles ‘overmedication’
stat
May 6, 26
Bayer to buy Perfuse Therapeutics for $300M upfront
endpoints
May 6, 26
Opinion: Dr. Glaucomflecken wants to make a stink
stat
May 5, 26
Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress
onclive
May 5, 26
Viridian data lift prospects for thyroid eye disease drug
biopharma dive
May 5, 26
Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech's $83M
endpoints
May 5, 26
STAT+: Are analysts too quick to gloss over Lilly’s liver case?
stat
← prev
page 5 of 6
next →
